Endoscopic Retrograde Cholangiopancreatography Market: Industry Analysis and Forecast (2024-2030)

Endoscopic Retrograde Cholangiopancreatography Market Overview:

The Endoscopic Retrograde Cholangiopancreatography market is segmented into product type, application, end-user and region. On the basis of product type, the Endoscopic Retrograde Cholangiopancreatography Market is segmented into Endoscopes, Endotherapy Devices, Imaging Devices and Energy Devices. On the basis of application, the market is segmented into Biliary Sphincterotomy, Biliary Dilatation, Biliary Stenting, Pancreatic Sphincterotomy, Pancreatic Duct Dilatation and Pancreatic Duct Stenting. On the basis of end-user, the market is segmented into Hospitals & Clinics, Ambulatory Surgery Centres and others. Geographically the Endoscopic Retrograde Cholangiopancreatography Market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America.

 

 

To get more Insights: Request Free Sample Report

 

Endoscopic Retrograde Cholangiopancreatography Market Dynamics:

The rise in incidences of gastrointestinal and chronic biliary disorders such as Barrett's disease, biliary disease, colitis, Crohn's disease, and gastroesophageal reflux disorder (GERD), liver disease, pancreatitis, inflammatory bowel disease, and peptic ulcer disease is driving the global endoscopic retrograde cholangiopancreatography (ERCP) market.

 

Also, the prevalence of benign tumors of the liver and pancreas is rapidly increasing, owing to an ageing population and increased awareness of equipment used in ERCP for the treatment of illnesses. However, the market for endoscopic retrograde cholangiopancreatography is projected to be hampered by high costs associated with ERCP therapy and adverse effects such as post-ERCP pancreatitis.

 

As the incidence of biliary stones and pancreatic cancer rises, demand for these Endoscopic Retrograde Cholangiopancreatography is projected to rise in the during the forecast period. After lung and bronchus cancer and colorectal cancer, pancreatic cancer is the third most frequent disease in the United States, with 60430 new cases and 48220 deaths, according to the American Cancer Society's Statistics 2021.

 

Pancreatic cancer will affect approximately 111500 people (55000 men and 56500 women) in the 28 countries of the European Union (EU) by 2025, with the number of recorded deaths increasing by nearly 50% (45 percent in men and 49 percent in women), making it the third leading cause of cancer death in the EU after lung and colorectal cancer.

 

Emerging countries, on the other hand, have a significant growth potential due to improvements in healthcare infrastructure. Endoscopy is a clinical procedure that allows doctors to examine body tissue or internal organs in more detail or do small surgery. Endoscopic Retrograde Cholangiopancreatography (ERCP) devices are medical devices used to diagnose and treat abnormalities of the pancreas and biliary system. Due to an increase in the prevalence of various bile duct, pancreatic, and liver disorders such as Barrett's Disease, Biliary Disease, Colitis, Crohn's Disease, Gastroesophageal Reflux Disorder (GERD), liver Disease, Pancreatitis, Inflammatory Bowel Disease, Crohn's Disease, and Peptic Ulcer Disease, these devices are gaining in importance and adoption.

 

Cancer is becoming more common over the world. According to the World Health Organization, cancer is the second biggest cause of death globally, accounting for 9.6 million deaths in 2018. The American Cancer Society predicts that 41,260 new cases of liver cancer and intrahepatic bile duct cancer will be detected in the United States in 2022. Since 1980, the incidence of liver cancer has more than tripled, while the fatality rate has more than doubled. Around 60,430 new pancreatic cases were detected in the United States in 2021. Every year, around 10,500 new pancreatic cancer cases and 6,200 new liver cancer cases are diagnosed in the United Kingdom.

 

Endoscopic Retrograde Cholangiopancreatography surgeries for treatment and diagnosis are becoming more common, and technological advancements are leading in more advanced applications, which are driving the Endoscopic Retrograde Cholangiopancreatography market forward. In partnership with the Ministry of Internal Affairs and Communications, Olympus Corporation conducted research named "Survey Study for International Expansion of AI Diagnosis Support System Using Ultra-High Magnifying Endoscopes in India" in October 2020. (MIC). The study's purpose is to improve endoscopic diagnosis in India, where endoscopists are in short supply. In collaboration with Cybernet Systems Co. Ltd., Olympus developed an AI diagnostic support system for the Asian Institute of Gastroenterology (AIG) in Hyderabad, India.

 

In terms of market restraints, the high prices of Endoscopic Retrograde Cholangiopancreatography equipment and procedures are one of the most significant market restraints. The typical cost of a duodenoscope ranges from USD 31,500 (non-HD) to USD 37,000 (HD). This is unfavorable because to the expensive price and lengthy treatment time as not a lot of patients are able to afford such costly diagnosis. In addition, according to an interview with an expert in the ERCP market, one of the main reasons why the process is not easily accessible and cheap to many small-scale end users that serve a big population, particularly in developing nations, is the cost.

 

 

People have become more interested in minimally invasive operations in recent years, rather than typical open surgeries that need large incisions through the muscles. It takes a long time for these muscles to recover. The main benefit of minimally invasive surgeries (MIS) over traditional open surgeries is higher precision due to video-assisted equipment, which produces a better and magnified image of the organs or body parts being operated on, as well as other significant benefits such as less major bleeding, fewer post-op infections, fewer complications, shorter length of stay, faster return to normal activities, less scarring, and comparable/lower cost, among other costs. As a result, these operations have recently grown more common amongst patients.

 

In terms of market restraints, high costs associated with endoscopic retrograde cholangiopancreatography (ECRP) devices, as well as side effects such as post-ERCP pancreatitis, infection, hemorrhage, and allergic reactions that are associated with cholangiopancreatography procedures, are expected to restrict the Endoscopic Retrograde Cholangiopancreatography market growth during the forecast period. Additionally, Endoscopic Retrograde Cholangiopancreatography (ECRP) devices use advanced techniques, they have a higher risk of significant consequences than other endoscopic procedures.

 

As a result, specialist equipment and training are necessary, and the process is carried out only under appropriate situations. The specialized equipment along with a highly trained doctor and a medical professional account for high cost of operation although it can be observed that the outcome of the operation would be more stable however high cost in itself is a market deterrent in this case for Endoscopic Retrograde Cholangiopancreatography.

 

The COVID-19 epidemic has had a significant influence on endoscopic services around the world. In addition, the virus was spread via contact and droplets. As a result, endoscopy providers faced a significant danger during the pandemic, as the disease spread mostly through direct touch or aerosol droplets, and endoscopic procedures ask for close physical proximity between patients and workers.

 

According to a Hong Kong article based on SARS experience, physicians have a 5% infection risk, nurses have a 4% infection risk, and healthcare assistants have an 8% infection risk. It stressed the need of maintaining rigorous isolation, infection management, and wearing personal protective equipment (PPE). As a result, the COVID-19 pandemic has had a detrimental influence on the endoscopic retrograde cholangiopancreatography business.

 

Endoscopic Retrograde Cholangiopancreatography Market Segment Analysis:

On the basis of product type, Endotherapy devices are projected to dominate the market in 2027 due to growth of gastrointestinal conditions and minimally invasive surgeries.

 

Furthermore, as demand for endoscopic procedures used for various pancreas and pancreas-related disorders develops, the endoscopic retrograde cholangiopancreatography market is predicted to grow. In terms of end user, the hospitals and clinics segment is projected to grow as major demand for ERC comes from hospitals where the initial test takes place.

 

Endoscopic Retrograde Cholangiopancreatography Market Regional Insights:

North America is projected to dominate the market due to increased R&D spending, presence of key players and their product availability, and the region's well-established healthcare infrastructure, and is projected to maintain its dominance from 2023 to 2029. Additionally, North America Endoscopic Retrograde Cholangiopancreatography Market is projected to grow during the forecast period at a significant rate because of rising incidence of cancer, large investments in new ERCP technology by hospitals, research centres and a significant focus on research activities to improve endoscopic techniques, these are all important factors that are fuelling the growth of Endoscopic Retrograde Cholangiopancreatography Market.

 

North America also has presence of key players in its region which emphasizes the importance of Endoscopic Retrograde Cholangiopancreatography Market and functions as a major driver. However, as governments in Asian region are spending in the betterment of healthcare infrastructure, Asia-Pacific region is predicted to have the highest CAGR during the forecast period.

 

The need for Endoscopic Retrograde Cholangiopancreatography equipment has increased in the APAC region, owing to a growing awareness of less invasive procedures among the aged population and the rising prevalence of chronic diseases. Furthermore, the APAC endoscopy devices market is expected to grow due to increased demand for endoscopes for treatment and diagnostics, as well as technical advances resulting in improved applications. The use of endoscopic retrograde cholangiopancreatography (ERCP) for children is growing fast in all the regions, based on the experience gained from adult ERCP procedures over the last 50 years.

 

In the past, the indications for endoscopic retrograde cholangiopancreatography and its perceived value in juvenile patients were limited because of the scarcity of pediatrics gastroenterologists with interventional endoscopy training, and hence pediatric ERCP treatments were traditionally performed by adult gastroenterologists. This practice trend has changed in the last 10-15 years, owing to an increase in the number of pediatric-trained interventional endoscopists who can safely and efficiently perform endoscopic retrograde cholangiopancreatography.

 

The objective of the report is to present a comprehensive analysis of the Endoscopic Retrograde Cholangiopancreatography market to the stakeholders in the industry. The report provides trends that are most dominant in the Endoscopic Retrograde Cholangiopancreatography market and how these trends will influence new business investments and market development throughout the forecast period. The report also aids in the comprehension of the Endoscopic Retrograde Cholangiopancreatography Market dynamics and competitive structure of the market by analyzing market leaders, market followers, and regional players.

 

The qualitative and quantitative data provided in the Endoscopic Retrograde Cholangiopancreatography market report is to help understand which market segments, regions are expected to grow at higher rates, factors affecting the market, and key opportunity areas, which will drive the industry and market growth through the forecast period. The report also includes the competitive landscape of key players in the industry along with their recent developments in the Endoscopic Retrograde Cholangiopancreatography market. The report studies factors such as company size, market share, market growth, revenue, production volume, and profits of the key players in the Endoscopic Retrograde Cholangiopancreatography market.

 

The report provides Porter's Five Force Model, which helps in designing the business strategies in the market. The report helps in identifying how many rivals exist, who they are, and how their product quality is in the Endoscopic Retrograde Cholangiopancreatography market. The report also analyses if the Endoscopic Retrograde Cholangiopancreatography market is easy for a new player to gain a foothold in the market, do they enter or exit the market regularly, if the market is dominated by a few players, etc.

 

The report also includes a PESTEL Analysis, which aids in the development of company strategies. Political variables help in figuring out how much a government can influence the Endoscopic Retrograde Cholangiopancreatography market. Economic variables aid in the analysis of economic performance drivers that have an impact on the Endoscopic Retrograde Cholangiopancreatography market. Understanding the impact of the surrounding environment and the influence of environmental concerns on the Endoscopic Retrograde Cholangiopancreatography market is aided by legal factors.

 

Endoscopic Retrograde Cholangiopancreatography Market Scope:

 

 

Endoscopic Retrograde Cholangiopancreatography Market
Market Size in 2023	USD 1.49 Bn.
Market Size in 2030	USD 2.49 Bn.
CAGR (2024-2030)	7.6  Percent
Historic Data	2018-2022
Base Year	2023
Forecast Period	2024-2030
Segment Scope	by Product Type           Endoscopes Endo therapy Devices Imaging Devices Energy Devices
	by Application Biliary Sphincterotomy Biliary Dilatation Biliary Stenting Pancreatic Sphincterotomy Pancreatic Duct Dilatation Pancreatic Duct Stenting
	by End-User Hospitals & Clinics Ambulatory Surgery Centers Others
Regional Scope	North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America

 

Endoscopic Retrograde Cholangiopancreatography Market Key Players

• Hobbs Medical, Inc. (US)
• Steris PLC (US)
• Merit Medical Systems, Inc. (US)
• TeleMed Systems, Inc. (US)
• Changzhou Health Microport Medical Device Co., LTD. (China)
• Medi-Globe GmbH (Germany)
• Taewoong Medical Co., Ltd. (South Korea)
• Huger Medical Instrument Co., Ltd. (China)
• IntroMedic Co., Ltd. (Republic of Korea)
• SonoScape Medical Corporation (China)
• Shanghai AOHUA Photoelectricity Endoscope Co., Ltd. (China)
• Ottomed (India)
• Kimberly-Clark Corporation (US)
• Shaili Endoscopy (India)
• Medtronic Plc (Ireland)
• Boston Scientific Corporation (US)
• Olympus Corporation (Japan)